Nuclear factor kappa B (NF-κB) in multiple sclerosis pathology

Trends in Molecular Medicine

Volumn 19, Issue 10, 2013, Pages 604-613

  Mc Guire, Conor ^a,b   Prinz, Marco ^c   Beyaert, Rudi ^a,b   van Loo, Geert ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Cuprizone; Demyelination; Experimental autoimmune encephalomyelitis; Multiple sclerosis; NF B; Th17

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TRANSCRIPTION FACTOR FOXP3;

ALLERGIC ENCEPHALOMYELITIS; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNITY; MULTIPLE SCLEROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

CUPRIZONE; DEMYELINATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE SCLEROSIS; NF-ΚB; TH17;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84884753706     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.08.001     Document Type: Review

References (124)

1. Oeckinghaus A., et al. Crosstalk in NF-kappaB signaling pathways. Nat. Immunol. 2011, 12:695-708.
2. Kaltschmidt B., Kaltschmidt C. NF-kappaB in the nervous system. Cold Spring Harb. Perspect. Biol. 2009, 1:a001271.
3. Nylander A., Hafler D.A. Multiple sclerosis. J. Clin. Invest. 2012, 122:1180-1188.
4. Goverman J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009, 9:393-407.
5. Ransohoff R.M. Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat. Neurosci. 2012, 15:1074-1077.
6. Gveric D., et al. Transcription factor NF-kappaB and inhibitor I kappaBalpha are localized in macrophages in active multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 1998, 57:168-178.
7. Bonetti B., et al. Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology. Am. J. Pathol. 1999, 155:1433-1438.
8. Lock C., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
9. Mycko M.P., et al. cDNA microarray analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain 2003, 126:1048-1057.
10. Whitney L.W., et al. Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 1999, 46:425-428.
11. Miterski B., et al. Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes Immun. 2002, 3:211-219.
12. Gilli F., et al. Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis. PLoS ONE 2010, 5:e8962.
13. De Jager P.L., et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 2009, 41:776-782.
14. Gilli F., et al. Loss of braking signals during inflammation: a factor affecting the development and disease course of multiple sclerosis. Arch. Neurol. 2011, 68:879-888.
15. Sawcer S., et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
16. Gregory A.P., et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012, 488:508-511.
17. Lindsey J.W., et al. Gene expression changes in multiple sclerosis relapse suggest activation of T and non-T cells. Mol. Med. 2011, 17:95-102.
18. Satoh J., et al. Molecular network analysis of T-cell transcriptome suggests aberrant regulation of gene expression by NF-kappaB as a biomarker for relapse of multiple sclerosis. Dis. Markers 2008, 25:27-35.
19. Kaileh M., Sen R. NF-kappaB function in B lymphocytes. Immunol. Rev. 2012, 246:254-271.
20. von Budingen H.C., et al. B cells in multiple sclerosis: connecting the dots. Curr. Opin. Immunol. 2011, 23:713-720.
21. Krumbholz M., et al. B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat. Rev. Neurol. 2012, 8:613-623.
22. Li Q., Verma I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2002, 2:725-734.
23. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
24. Baxter A.G. The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 2007, 7:904-912.
25. + T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J. Exp. Med. 2003, 197:861-874.
26. Kontgen F., et al. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes Dev. 1995, 9:1965-1977.
27. Liou H.C., et al. c-Rel is crucial for lymphocyte proliferation but dispensable for T cell effector function. Int. Immunol. 1999, 11:361-371.
28. Hilliard B.A., et al. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J. Clin. Invest. 2002, 110:843-850.
29. Becher B., Segal B.M. T(H)17 cytokines in autoimmune neuro-inflammation. Curr. Opin. Immunol. 2011, 23:707-712.
30. Chen G., et al. The NF-kappaB transcription factor c-Rel is required for Th17 effector cell development in experimental autoimmune encephalomyelitis. J. Immunol. 2011, 187:4483-4491.
31. Ruan Q., et al. The Th17 immune response is controlled by the Rel-RORgamma-RORgamma T transcriptional axis. J. Exp. Med. 2011, 208:2321-2333.
32. Codarri L., et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 2011, 12:560-567.
33. El-Behi M., et al. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 2011, 12:568-575.
34. Haak S., et al. IL-17A and IL-17F do not contribute vitally to autoimmune neuro-inflammation in mice. J. Clin. Invest. 2009, 119:61-69.
35. Sonderegger I., et al. IL-21 and IL-21R are not required for development of Th17 cells and autoimmunity in vivo. Eur. J. Immunol. 2008, 38:1833-1838.
36. Gerondakis S., et al. Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:3405-3409.
37. Himes S.R., et al. High mobility group protein I(Y) is required for function and for c-Rel binding to CD28 response elements within the GM-CSF and IL-2 promoters. Immunity 1996, 5:479-489.
38. + CD4 regulatory T cells. J. Exp. Med. 2009, 206:3001-3014.
39. + T cells but not T(H)17 cells. Eur. J. Immunol. 2010, 40:671-676.
40. Zheng Y., et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010, 463:808-812.
41. Beg A.A., et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 1995, 376:167-170.
42. Doi T.S., et al. NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J. Exp. Med. 1997, 185:953-961.
43. Powolny-Budnicka I., et al. RelA and RelB transcription factors in distinct thymocyte populations control lymphotoxin-dependent interleukin-17 production in gammadelta T cells. Immunity 2011, 34:364-374.
44. Pahan K., Schmid M. Activation of nuclear factor-kB in the spinal cord of experimental allergic encephalomyelitis. Neurosci. Lett. 2000, 287:17-20.
45. Hwang I., et al. Experimental autoimmune encephalomyelitis: association with mutual regulation of RelA (p65)/NF-kappaB and phospho-IkappaB in the CNS. Biochem. Biophys. Res. Commun. 2011, 411:464-470.
46. Algul H., et al. Pancreas-specific RelA/p65 truncation increases susceptibility of acini to inflammation-associated cell death following cerulein pancreatitis. J. Clin. Invest. 2007, 117:1490-1501.
47. Steinbrecher K.A., et al. Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation. J. Immunol. 2008, 180:2588-2599.
48. Hilliard B., et al. Experimental autoimmune encephalomyelitis in NF-kappa B-deficient mice:roles of NF-kappa B in the activation and differentiation of autoreactive T cells. J. Immunol. 1999, 163:2937-2943.
49. Das J., et al. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol. 2001, 2:45-50.
50. Jager A., et al. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 2009, 183:7169-7177.
51. O'Donnell S.M., et al. Organ-specific roles for transcription factor NF-kappaB in reovirus-induced apoptosis and disease. J. Clin. Invest. 2005, 115:2341-2350.
52. Staal J., et al. Regulation of NF-kappaB signaling by caspases and MALT1 paracaspase. Cell Res. 2011, 21:40-54.
53. Egawa T., et al. Requirement for CARMA1 in antigen receptor-induced NF-kappa B activation and lymphocyte proliferation. Curr. Biol. 2003, 13:1252-1258.
54. Hara H., et al. The MAGUK family protein CARD11 is essential for lymphocyte activation. Immunity 2003, 18:763-775.
55. Ruefli-Brasse A.A., et al. Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science 2003, 302:1581-1584.
56. Ruland J., et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell 2001, 104:33-42.
57. Ruland J., et al. Differential requirement for Malt1 in T and B cell antigen receptor signaling. Immunity 2003, 19:749-758.
58. Brustle A., et al. The NF-kappaB regulator MALT1 determines the encephalitogenic potential of Th17 cells. J. Clin. Invest. 2012, 122:4698-4709.
59. Mc Guire C., et al. Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination. J. Immunol. 2013, 190:2896-2903.
60. Molinero L.L., et al. T cell receptor/CARMA1/NF-kappaB signaling controls T-helper (Th) 17 differentiation. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:18529-18534.
61. Coornaert B., et al. T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20. Nat. Immunol. 2008, 9:263-271.
62. Hailfinger S., et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:19946-19951.
63. Rebeaud F., et al. The proteolytic activity of the paracaspase MALT1 is key in T cell activation. Nat. Immunol. 2008, 9:272-281.
64. Staal J., et al. T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. EMBO J. 2011, 30:1742-1752.
65. Hailfinger S., et al. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14596-14601.
66. Schmidt-Supprian M., et al. Mature T cells depend on signaling through the IKK complex. Immunity 2003, 19:377-389.
67. Schmidt-Supprian M., et al. I kappa B kinase 2 deficiency in T cells leads to defects in priming, B cell help, germinal center reactions, and homeostatic expansion. J. Immunol. 2004, 173:1612-1619.
68. + regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:4566-4571.
69. Greve B., et al. I kappa B kinase 2/beta deficiency controls expansion of autoreactive T cells and suppresses experimental autoimmune encephalomyelitis. J. Immunol. 2007, 179:179-185.
70. Weih F., et al. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 1995, 80:331-340.
71. Corn R.A., et al. Opposing roles for RelB and Bcl-3 in regulation of T-box expressed in T cells, GATA-3, and Th effector differentiation. J. Immunol. 2005, 175:2102-2110.
72. Li L., et al. Transcriptional regulation of the Th17 immune response by IKK(alpha). J. Exp. Med. 2011, 208:787-796.
73. Petermann F., et al. γδ T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity 2010, 33:351-363.
74. Gocke A.R., et al. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J. Immunol. 2007, 178:1341-1348.
75. Sutton C.E., et al. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
76. Marienfeld R., et al. RelB forms transcriptionally inactive complexes with RelA/p65. J. Biol. Chem. 2003, 278:19852-19860.
77. Jin W., et al. Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Blood 2009, 113:6603-6610.
78. Hofmann J., et al. NIK signaling in dendritic cells but not in T cells is required for the development of effector T cells and cell-mediated immune responses. J. Exp. Med. 2011, 208:1917-1929.
79. Mattson M.P., Meffert M.K. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ. 2006, 13:852-860.
80. Schneider A., et al. NF-kappaB is activated and promotes cell death in focal cerebral ischemia. Nat. Med. 1999, 5:554-559.
81. Yu Z., et al. Lack of the p50 subunit of nuclear factor-kappaB increases the vulnerability of hippocampal neurons to excitotoxic injury. J. Neurosci. 1999, 19:8856-8865.
82. Fridmacher V., et al. Forebrain-specific neuronal inhibition of nuclear factor-kappaB activity leads to loss of neuroprotection. J. Neurosci. 2003, 23:9403-9408.
83. van Loo G., et al. Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat. Immunol. 2006, 7:954-961.
84. Emmanouil M., et al. Neuronal I kappa B kinase beta protects mice from autoimmune encephalomyelitis by mediating neuroprotective and immunosuppressive effects in the central nervous system. J. Immunol. 2009, 183:7877-7889.
85. Taoufik E., et al. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB. Brain 2011, 134:2722-2735.
86. Brambilla R., et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain 2011, 134:2736-2754.
87. Gimenez M.A., et al. TNFR1-dependent VCAM-1 expression by astrocytes exposes the CNS to destructive inflammation. J. Neuroimmunol. 2004, 151:116-125.
88. Brambilla R., et al. Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J. Immunol. 2009, 182:2628-2640.
89. + regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. J. Immunol. 2008, 180:825-832.
90. Mangalam A.K., et al. Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice. J. Autoimmun. 2012, 38:344-353.
91. + Treg. Eur. J. Immunol. 2009, 39:2106-2119.
92. Oeckl P., et al. Astrocyte-specific IKK2 activation in mice is sufficient to induce neuroinflammation but does not increase susceptibility to MPTP. Neurobiol. Dis. 2012, 48:481-487.
93. Lee D.H., et al. Neuronal NF-kappaB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination. J. Neuroimmunol. 2012, 246:38-42.
94. Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol. 2009, 19:404-413.
95. Roget K., et al. IkappaB kinase 2 regulates TPL-2 activation of extracellular signal-regulated kinases 1 and 2 by direct phosphorylation of TPL-2 serine 400. Mol. Cell. Biol. 2012, 32:4684-4690.
96. -/- mice exhibit Th1 cell polarization and increased susceptibility to experimental autoimmune encephalomyelitis. J. Immunol. 2006, 176:5788-5796.
97. Pernet V., et al. Extracellular signal-regulated kinase 1/2 mediates survival, but not axon regeneration, of adult injured central nervous system neurons in vivo. J. Neurochem. 2005, 93:72-83.
98. Ishii A., et al. ERK1/ERK2 MAPK signaling is required to increase myelin thickness independent of oligodendrocyte differentiation and initiation of myelination. J. Neurosci. 2012, 32:8855-8864.
99. Raasch J., et al. IkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappaB in the central nervous system. Brain 2011, 134:1184-1198.
100. Ellrichmann G., et al. Constitutive activity of NF-kappa B in myeloid cells drives pathogenicity of monocytes and macrophages during autoimmune neuroinflammation. J. Neuroinflammation 2012, 9:15.
101. Sun X., et al. Myelin activates FAK/Akt/NF-kappaB pathways and provokes CR3-dependent inflammatory response in murine system. PLoS ONE 2010, 5:e9380.
102. Cho I.H., et al. Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain 2008, 131:3019-3033.
103. + myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 2009, 113:3190-3197.
104. +Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 2009, 132:2487-2500.
105. Nickols J.C., et al. Activation of the transcription factor NF-kappaB in Schwann cells is required for peripheral myelin formation. Nat. Neurosci. 2003, 6:161-167.
106. Morton P.D., et al. Activation of NF-kappaB in Schwann cells is dispensable for myelination in vivo. J. Neurosci. 2013, 33:9932-9936.
107. Arnett H.A., et al. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. 2001, 4:1116-1122.
108. Mason J.L., et al. Interleukin-1beta promotes repair of the CNS. J. Neurosci. 2001, 21:7046-7052.
109. Gao X., et al. Interferon-gamma protects against cuprizone-induced demyelination. Mol. Cell. Neurosci. 2000, 16:338-349.
110. Patel J.R., et al. CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11062-11067.
111. Yan J., Greer J.M. NF-kappa B, a potential therapeutic target for the treatment of multiple sclerosis. CNS Neurol. Disord. Drug Targets 2008, 7:536-557.
112. Aktas O., et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 2004, 173:5794-5800.
113. Jia Y., et al. Amelioration of experimental autoimmune encephalomyelitis by plumbagin through down-regulation of JAK-STAT and NF-kappaB signaling pathways. PLoS ONE 2011, 6:e27006.
114. Natarajan C., Bright J.J. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J. Immunol. 2002, 168:6506-6513.
115. van Loo G., et al. Antiinflammatory properties of a plant-derived nonsteroidal, dissociated glucocorticoid receptor modulator in experimental autoimmune encephalomyelitis. Mol. Endocrinol. 2010, 24:310-322.
116. Weston P.G., Johnston P.V. Incidence and severity of experimental allergic encephalomyelitis and cerebral prostaglandin synthesis in essential fatty acid deficient and aspirin-treated rats. Lipids 1978, 13:867-872.
117. Yin M.J., et al. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
118. Dasgupta S., et al. Antineuroinflammatory effect of NF-kappaB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J. Immunol. 2004, 173:1344-1354.
119. Tischner D., Reichardt H.M. Glucocorticoids in the control of neuroinflammation. Mol. Cell. Endocrinol. 2007, 275:62-70.
120. Epinat J.C., Gilmore T.D. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 1999, 18:6896-6909.
121. Zula J.A., et al. The role of cell type-specific responses in IFN-beta therapy of multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:19689-19694.
122. Bruck W., et al. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012, 124:411-424.
123. Fontan L., et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 2012, 22:812-824.
124. Nagel D., et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 2012, 22:825-837.